Davis C L, Gretch D R, Carithers R L
University of Washington Medical Center, Transplantation Services, Seattle 98195.
Curr Opin Nephrol Hypertens. 1994 Mar;3(2):164-73. doi: 10.1097/00041552-199403000-00006.
Hepatitis C virus (HCV) is the most frequent cause of liver disease in dialysis and renal transplant recipients. Approximately 20% to 30% of the dialysis population is infected with HCV. HCV is also recognized as a cause of membranoproliferative and membranous glomerulonephritis. Enzyme immunoassay or recombinant immunoblot assay identify antibodies to multiple HCV antigens and are useful in the diagnosis of HCV infection, including infections in dialysis patients. However, after transplantation, HCV RNA identification by polymerase chain reaction is often required to detect the infection. The natural history of HCV infection using the new viral markers remains to be defined in patients treated for end-stage renal disease.
丙型肝炎病毒（HCV）是透析患者和肾移植受者肝病最常见的病因。约20%至30%的透析人群感染了HCV。HCV也被认为是膜增生性和膜性肾小球肾炎的病因。酶免疫测定或重组免疫印迹测定可识别针对多种HCV抗原的抗体，对HCV感染的诊断，包括透析患者的感染诊断很有用。然而，移植后，通常需要通过聚合酶链反应进行HCV RNA鉴定来检测感染。使用新病毒标志物的HCV感染自然史在接受终末期肾病治疗的患者中仍有待确定。
